NAS:FMI (USA) Also trade in: Germany

Foundation Medicine Inc

$ 137 0 (0%)
Volume: 0 Avg Vol (1m): 0
Market Cap $: 5.09 Bil Enterprise Value $: 5.14 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -31.31
Net Current Asset Value -1.75
Tangible Book -0.23
Projected FCF -21.05
Median P/S Value 45.94
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.49
Equity-to-Asset -0.04
Debt-to-Equity -12.89
Debt-to-EBITDA -0.93
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.10
DISTRESS
GREY
SAFE
Beneish M-Score -2.55
Not Manipulator
Manipulator

Profitability & Growth : 4/10

Current vs industry vs history
Operating Margin % -68.74
Net Margin % -70.28
ROE % -362.98
ROA % -84.60
ROC (Joel Greenblatt) % -321.63
3-Year Total Revenue Growth Rate 35.80
3-Year Total EBITDA Growth Rate -46.70
3-Year EPS w/o NRI Growth Rate -34.00

» FMI's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:FMI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare BSP:DASA3 SHSE:603658 BSP:FLRY3 TSE:4544 NAS:SYNH SHSE:603882 SZSE:300463 NAS:MYGN SZSE:300244 NAS:QDEL SZSE:300482 NAS:NEOG NAS:ABAX NAS:BRKR NAS:VREX SHSE:603108 NAS:AXDX SZSE:300685 BSP:PARD3 NAS:KANG
Traded in other countries 8FM.Germany
Address
Foundation Medicine Inc is a molecular diagnostics company that specializes in the evaluation and treatment of cancer. Its products provide genetic information about a patient's cancer that is used by physicians to inform clinical decisions and by biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine's core molecular information products include FoundationOne, for solid tumors, and FoundationOne Heme, for blood-based cancers and hematologic malignancies. The vast majority of the firm's revenue is generated within the United States.

Ratios

Current vs industry vs history
PS Ratio 24.90
EV-to-EBIT -37.16
EV-to-EBITDA -43.58
EV-to-Revenue 25.54
Current Ratio 1.68
Quick Ratio 1.36
Days Inventory 54.34
Days Sales Outstanding 74.19
Days Payable 104.85

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.00

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 2.98
Earnings Yield (Joel Greenblatt) % -2.69

More Statistics

Revenue (TTM) (Mil) $ 201.42
EPS (TTM) $ -3.87
Beta 0
Volatility % 49.46
52-Week Range $ 35.11 - 137.2
Shares Outstanding (Mil) 37.24

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y